| 000 | 01661 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516122523.0 | ||
| 264 | 0 | _c20130814 | |
| 008 | 201308s 0 0 eng d | ||
| 022 | _a1476-5381 | ||
| 024 | 7 |
_a10.1111/bph.12065 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBoehlen, A | |
| 245 | 0 | 0 |
_aThe new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential. _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _cMar 2013 |
||
| 300 |
_a1182-200 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAmygdala _xdrug effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnticonvulsants _xpharmacology |
| 650 | 0 | 4 |
_aBenzamides _xpharmacology |
| 650 | 0 | 4 |
_aCA1 Region, Hippocampal _xdrug effects |
| 650 | 0 | 4 | _aCHO Cells |
| 650 | 0 | 4 |
_aCarbamates _xpharmacology |
| 650 | 0 | 4 | _aCricetinae |
| 650 | 0 | 4 | _aCricetulus |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aKCNQ2 Potassium Channel _xagonists |
| 650 | 0 | 4 | _aOocytes |
| 650 | 0 | 4 |
_aPhenylenediamines _xpharmacology |
| 650 | 0 | 4 |
_aPyramidal Cells _xdrug effects |
| 650 | 0 | 4 |
_aPyridines _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aSynaptic Transmission _xdrug effects |
| 650 | 0 | 4 | _aXenopus laevis |
| 700 | 1 | _aSchwake, M | |
| 700 | 1 | _aDost, R | |
| 700 | 1 | _aKunert, A | |
| 700 | 1 | _aFidzinski, P | |
| 700 | 1 | _aHeinemann, U | |
| 700 | 1 | _aGebhardt, C | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 168 _gno. 5 _gp. 1182-200 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/bph.12065 _zAvailable from publisher's website |
| 999 |
_c22286701 _d22286701 |
||